# James Zhao > James Zhao is a Series B investor at LYFE Capital backing Biotechnology and Pharmaceutical. See 3 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [LYFE Capital](https://shizune.co/investors/profile/lyfe-capital-2) - Location: Menlo Park, United States - Total investments: 3 - Last investment: Jul 2021 - Lead investor: 67% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/james-zhao-a4a2254 James Zhao is a Series B investor at LYFE Capital in Menlo Park focused on Biotechnology and Pharmaceutical. James Zhao is based out of Menlo Park, California and is the Founder and Partner of LYFE Capital. James previously worked at Vivo Capital as a Vivo Capital. James Zhao attended the Olin Business School at Washington University. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Biotechnology | 2 | 67% | | Pharmaceutical | 2 | 67% | | Biopharma | 1 | 33% | | Health Care | 1 | 33% | | Therapeutics | 1 | 33% | ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series B | 2 | 67% | | Series C | 1 | 33% | ### Country | Country | Investments | Share | | --- | --- | --- | | China | 1 | 33% | | France | 1 | 33% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Hugo Biotech | Hugo Biotech has conducted the sequencing of nearly 20,000 clinical samples for over 300 first class hospitals in china. | $30.8M | Series B | Jul 20, 2021 | | | HiFiBiO Therapeutics | HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rootedbiological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders.The company was founded in 2013 and is headquartered in Paris, Ille-de-France. | $67M | Series C | Aug 28, 2019 | | | HiFiBiO Therapeutics | HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rootedbiological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders.The company was founded in 2013 and is headquartered in Paris, Ille-de-France. | $37.5M | Series B | May 16, 2018 | | 3 of 3 investments shown. ## Co-investors - [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 2 deals together - [Legend Star](https://shizune.co/investors/profile/legendstar) — VC Fund, 2 deals together - [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund, 2 deals together - [Sinovation Ventures](https://shizune.co/investors/profile/sinovation-ventures) — VC Fund, 2 deals together - [Delian Capital](https://shizune.co/investors/profile/delian-capital) — VC Fund, 1 deal together - [Hanne Capital](https://shizune.co/investors/profile/hanne-capital) — VC Fund, 1 deal together ## About LYFE Capital VC Fund · Shanghai, China LYFE Capital is a pure play healthcare focused investment firm. We believe that “Healthcare has no boundaries”, and that every new choice we made has the potential to advance healthcare and solve the unmet needs for everyone. LYFE Capital operates 5 global offices including our US headquarters in Menlo Park, California, our Asia headquarters inSingapore, as well as locations in Seoul, Tokyo and Shanghai. We leverage our expertise and global resources to invest in and create value for healthcare companies across the globe. LYFE Capital’s investments span medical devices, therapeutics, diagnostics, and emerging sectors across North America and Asia. 4 contacts available at LYFE Capital. | Name | Title | Profile | | --- | --- | --- | | James Zhao | Founder and Partner | https://shizune.co/investors/profile/james-zhao | | Drake Yu | Founder | https://shizune.co/investors/profile/drake-yu | | Roy Xu | CFO | https://shizune.co/investors/profile/roy-xu | | Wang Yinan | Partner | https://shizune.co/investors/profile/wang-yinan-60b5 | ## Similar investors ### Similar stage - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund - [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund ## FAQ ### What does James Zhao invest in? James Zhao invests primarily in Biotechnology, Pharmaceutical and Biopharma startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did James Zhao last invest? The most recent investment recorded for James Zhao closed in Jul 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co